A Study of ICP-192 in Patients With Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2023-02-16
Target enrollment:
Participant gender:
Summary
This is a multi-center, open-label, phase I/II clinical study to evaluate ICP-192 in patients
with advanced solid tumors and FGFR gene alterations. It consists of two parts: Part I (Phase
I), dose escalation and Part II (Phase II), dose expansion.